Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Genotype is the missing clue in electromagnetic hypersensitivity (EHS). Two lines of research now show that the same EMF exposure does not land the same way in every person or cell — because the “receiver biology” differs. • CACNA1C (Cav1.2 calcium channel gene): A common non-coding variant (rs7304986) determined...

rfsafe's profile picture

RF Safe

3,453 subscribers

44,201 görüntüleme • 1 ay önce •via X (Twitter)

Bilim & Teknoloji
LIVE

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

TRANSFORMATION: A Third Option in Human Biology In nearly every disease, from cancer to Alzheimer’s, cells face two fates: Die. Or survive. But what if we could transform them? That’s what I discovered. This isn't stem cells. This is genetics. Most therapies kill cells (apoptosis) or let them live damaged (survival). But through decoupling PI3K and MTOR among other inside the cell pathways, I found a way to guide cells to reprogram from diseased to healthy. In Jill’s case, this produced 10 molecular “impossibles.” 10 human first biomedical results. It reactivated silenced genes. It reduced tumors. And it did so without killing the cell with the healthy genes being restored. For non-cancer disorders like Severe autism, Alzheimer’s, Huntington's that are genetic degeneration or de-development - transformation is the only way. This is the future of therapeutics: Not war. Not stalling. But biological transformation.
9:11

TRANSFORMATION: A Third Option in Human Biology In nearly every disease, from cancer to Alzheimer’s, cells face two fates: Die. Or survive. But what if we could transform them? That’s what I discovered. This isn't stem cells. This is genetics. Most therapies kill cells (apoptosis) or let them live damaged (survival). But through decoupling PI3K and MTOR among other inside the cell pathways, I found a way to guide cells to reprogram from diseased to healthy. In Jill’s case, this produced 10 molecular “impossibles.” 10 human first biomedical results. It reactivated silenced genes. It reduced tumors. And it did so without killing the cell with the healthy genes being restored. For non-cancer disorders like Severe autism, Alzheimer’s, Huntington's that are genetic degeneration or de-development - transformation is the only way. This is the future of therapeutics: Not war. Not stalling. But biological transformation.

Marc Malone

22,753 görüntüleme • 10 ay önce

Chemotherapy kills the very cells the body uses to fight cancer. A surgeon and cancer researcher just said it out loud to a national audience, and the science backing him up is growing fast. Jefferey Jaxen opens with Dr. Patrick Soon-Shiong, who told Tucker Carlson that 99.9% of oncologists pay no attention to lymphocytes, the natural killer cells and T cells that are the immune system's actual weapon against cancer, and that chemotherapy's brief response is followed by metastasis because the treatment eliminates the body's protection. The research community is beginning to build in a different direction. Researchers at Trinity College Dublin have demonstrated that interferon gamma, a naturally occurring signaling protein that activates T cells and macrophages, can be used to train immune cells before they encounter a pathogen, thereby enhancing the killing of drug-resistant tuberculosis and MRSA staph infections in both healthy and genetically vulnerable individuals. The implications reach beyond antibiotic resistance: the same principle suggests that targeted immune training for immunosuppressed individuals could replace the current practice of blanket vaccination of entire populations to protect a few. Also reported last month, a UCLA study and subsequent meta-analysis found that honeybee venom and its primary protein, melittin, induced massive cell death in triple-negative and HER2-enriched breast cancer cell lines within 60 minutes of treatment, disrupting receptor pathways that aggressive breast cancers depend on. Melittin is globally available, cost-effective, and accessible in remote regions. None of these treatments are available off the shelf yet, but the direction of the research, working with the immune system and drawing from natural environments rather than suppressing the body's own defenses, represents a genuine paradigm shift that would have been unlikely to receive funding a decade ago.
11:52

Chemotherapy kills the very cells the body uses to fight cancer. A surgeon and cancer researcher just said it out loud to a national audience, and the science backing him up is growing fast. Jefferey Jaxen opens with Dr. Patrick Soon-Shiong, who told Tucker Carlson that 99.9% of oncologists pay no attention to lymphocytes, the natural killer cells and T cells that are the immune system's actual weapon against cancer, and that chemotherapy's brief response is followed by metastasis because the treatment eliminates the body's protection. The research community is beginning to build in a different direction. Researchers at Trinity College Dublin have demonstrated that interferon gamma, a naturally occurring signaling protein that activates T cells and macrophages, can be used to train immune cells before they encounter a pathogen, thereby enhancing the killing of drug-resistant tuberculosis and MRSA staph infections in both healthy and genetically vulnerable individuals. The implications reach beyond antibiotic resistance: the same principle suggests that targeted immune training for immunosuppressed individuals could replace the current practice of blanket vaccination of entire populations to protect a few. Also reported last month, a UCLA study and subsequent meta-analysis found that honeybee venom and its primary protein, melittin, induced massive cell death in triple-negative and HER2-enriched breast cancer cell lines within 60 minutes of treatment, disrupting receptor pathways that aggressive breast cancers depend on. Melittin is globally available, cost-effective, and accessible in remote regions. None of these treatments are available off the shelf yet, but the direction of the research, working with the immune system and drawing from natural environments rather than suppressing the body's own defenses, represents a genuine paradigm shift that would have been unlikely to receive funding a decade ago.

The HighWire

12,182 görüntüleme • 3 ay önce

🚨🚨🚨 Dutch Cancer Researcher and Erasmus Medical Centre Assc Prof Maarten Fornerod discusses DNA contamination in COVID Vaccines. ---------------------------- ...for last 35 years or so I've been working uh in the areas of molecular biology, gene expression, biology, cancer biology and recently in the last years, maybe last 10 years in the context of big data and computational biology... ...when we use genetic vaccines what we do essentially is we're making a complex intervention in a very complex system. It's impossible to predict what happens if you combine these two complex systems, and you get unpredictable effects. .. And the only way to go about this is to do genotoxic research, when you want to introduce a genetic medicine into a human being and that genetotic research has to be independent, it has to be double blind, has to be long lasting. AND ALL THESE HAVE NOT BEEN DONE WITH THE GENETIC CORONA VACCINES! if there's a vaccine, there's a little bit of DNA in there upon injection that is very, very rapidly degraded by the human body. However if it's protected and in a lipid nanoarticle it can very efficiently be transduced in the cell... I've been doing this this many, many times. This is called lipofection and it's a very efficient way to introduce DNA into a cell. ...Many people think that this is not possible. But I've been working in nuclear transport for many years, I think more than 10 years. So I've been exposed to a lot of molecular cell biology of nuclear cytoplasmic transport. And it's clear that the DNA can enter the nucleus. Now to make things worse, the mRNA vaccine doesn't stay in the arm but it's detected in , in all different organs including the reproductive system. And so partly this is based on animal models, of course we know from Michael Morz that he has detected uh the spike protein in brain, in the heart and it's for sure it's detected in the blood and even in breast milk. ..So there's NO DOUBT that this mRNA vaccine spreads widely in the human body. ..Now from a genetic point of view, there are possible consequences uh of this and the consequences could be a 1. long term disruption of cellular processes that could lead to disease. 2. there's a risk of insertional mutageenesis in somatic cells that can lead to cancer. 3. the insertion mutogenesis takes place in a germ cell which would be a hereditary burden uh on the human population. 4. And you could also think that these um DNAs, could transfect the microbiome and it could possibly lead to bacterial resistance. So these are all possible..the consequences of these genetic vaccines in my view, the shortcomings in this rollout of these vaccines were there was no genotoxic research performed at all. There was no safety studies, on carcinogenic potential of these vaccines. My personal opinion is that it's now not a question of whether, it will integrate in recipient's DNA, but how often it occurs... It's just a numbers game. If you do this in many cells, many persons it will no doubt integrate in cells in human recipients. So the question does it affect the human genome? I would say it probably, I think it most certainly does. And you see Kevin McKernan here and he represented ah a preliminary data where he detected a possible Pfizer DNA in colon cancer biopsy one year after vaccination.
6:25

🚨🚨🚨 Dutch Cancer Researcher and Erasmus Medical Centre Assc Prof Maarten Fornerod discusses DNA contamination in COVID Vaccines. ---------------------------- ...for last 35 years or so I've been working uh in the areas of molecular biology, gene expression, biology, cancer biology and recently in the last years, maybe last 10 years in the context of big data and computational biology... ...when we use genetic vaccines what we do essentially is we're making a complex intervention in a very complex system. It's impossible to predict what happens if you combine these two complex systems, and you get unpredictable effects. .. And the only way to go about this is to do genotoxic research, when you want to introduce a genetic medicine into a human being and that genetotic research has to be independent, it has to be double blind, has to be long lasting. AND ALL THESE HAVE NOT BEEN DONE WITH THE GENETIC CORONA VACCINES! if there's a vaccine, there's a little bit of DNA in there upon injection that is very, very rapidly degraded by the human body. However if it's protected and in a lipid nanoarticle it can very efficiently be transduced in the cell... I've been doing this this many, many times. This is called lipofection and it's a very efficient way to introduce DNA into a cell. ...Many people think that this is not possible. But I've been working in nuclear transport for many years, I think more than 10 years. So I've been exposed to a lot of molecular cell biology of nuclear cytoplasmic transport. And it's clear that the DNA can enter the nucleus. Now to make things worse, the mRNA vaccine doesn't stay in the arm but it's detected in , in all different organs including the reproductive system. And so partly this is based on animal models, of course we know from Michael Morz that he has detected uh the spike protein in brain, in the heart and it's for sure it's detected in the blood and even in breast milk. ..So there's NO DOUBT that this mRNA vaccine spreads widely in the human body. ..Now from a genetic point of view, there are possible consequences uh of this and the consequences could be a 1. long term disruption of cellular processes that could lead to disease. 2. there's a risk of insertional mutageenesis in somatic cells that can lead to cancer. 3. the insertion mutogenesis takes place in a germ cell which would be a hereditary burden uh on the human population. 4. And you could also think that these um DNAs, could transfect the microbiome and it could possibly lead to bacterial resistance. So these are all possible..the consequences of these genetic vaccines in my view, the shortcomings in this rollout of these vaccines were there was no genotoxic research performed at all. There was no safety studies, on carcinogenic potential of these vaccines. My personal opinion is that it's now not a question of whether, it will integrate in recipient's DNA, but how often it occurs... It's just a numbers game. If you do this in many cells, many persons it will no doubt integrate in cells in human recipients. So the question does it affect the human genome? I would say it probably, I think it most certainly does. And you see Kevin McKernan here and he represented ah a preliminary data where he detected a possible Pfizer DNA in colon cancer biopsy one year after vaccination.

aussie17

126,273 görüntüleme • 1 yıl önce

David Sinclair just told Joe Rogan he takes Viagra every day for his hair. Then he dropped the real twist. The same class of drugs (low-dose tadalafil) is turning up in cancer data, stripping the immune shield tumors hide behind and blocking how cancer cells use cholesterol. That casual pivot was pleasantly surprising to me. A molecule we wrote off as a bedroom drug is quietly rewriting maps of immune surveillance, lipid trafficking, and even scalp perfusion at the same time. Biology refuses the neat boxes we drew for it. Most side effects were never side effects. They were just the parts of the system we had not bothered to measure yet. Human trials (especially head-and-neck) and multiple mouse models confirm tadalafil reduces myeloid-derived suppressor cells and restores T-cell access to tumors. A July 2026 Cancer Research paper showed sildenafil (same PDE5 class) traps cholesterol inside lysosomes via cGMP, limiting metastasis, an effect expected across the class. Hair evidence is still mostly mechanistic. Promising signals, not settled prevention. Viagra and its analogues are still mainly linked to the bedroom in most people’s minds. But with cancer rates rising in younger people, every possible avenue is worth exploring. We cannot afford to overlook tools just because of the box we first put them in.
1:45

David Sinclair just told Joe Rogan he takes Viagra every day for his hair. Then he dropped the real twist. The same class of drugs (low-dose tadalafil) is turning up in cancer data, stripping the immune shield tumors hide behind and blocking how cancer cells use cholesterol. That casual pivot was pleasantly surprising to me. A molecule we wrote off as a bedroom drug is quietly rewriting maps of immune surveillance, lipid trafficking, and even scalp perfusion at the same time. Biology refuses the neat boxes we drew for it. Most side effects were never side effects. They were just the parts of the system we had not bothered to measure yet. Human trials (especially head-and-neck) and multiple mouse models confirm tadalafil reduces myeloid-derived suppressor cells and restores T-cell access to tumors. A July 2026 Cancer Research paper showed sildenafil (same PDE5 class) traps cholesterol inside lysosomes via cGMP, limiting metastasis, an effect expected across the class. Hair evidence is still mostly mechanistic. Promising signals, not settled prevention. Viagra and its analogues are still mainly linked to the bedroom in most people’s minds. But with cancer rates rising in younger people, every possible avenue is worth exploring. We cannot afford to overlook tools just because of the box we first put them in.

Camus

613,933 görüntüleme • 1 ay önce

Cancer Has a Proven Frequency “Kill Switch” 🧬⚡️ In 1986, the US Government granted Patent 4,622,952 for a technology that destroys cancer cells with zero side effects. No chemo. No radiation. Just resonance. The science is based on a narrow 1°C thermal window: cancer cells die at 45.5°C, while healthy cells can survive up to 46.5°C. The Gordon Method: 📍 Resonant Absorption: Every cell vibrates at a specific frequency. Cancer cells, with their altered DNA, have a different “signature” than healthy cells. 📍 Internal Heating: By sweeping an EM field to 450 kHz, only the cancer cells absorb energy. They heat from the inside out and disintegrate. 📍 The Result: Healthy tissue remains unaffected because it isn’t “tuned” to that frequency. It was tested, it worked, and it was buried. Why? Because a one-time frequency treatment doesn’t create the recurring revenue of chemotherapy. [h/t HarmonicEarthTheory on IG]
2:55

Cancer Has a Proven Frequency “Kill Switch” 🧬⚡️ In 1986, the US Government granted Patent 4,622,952 for a technology that destroys cancer cells with zero side effects. No chemo. No radiation. Just resonance. The science is based on a narrow 1°C thermal window: cancer cells die at 45.5°C, while healthy cells can survive up to 46.5°C. The Gordon Method: 📍 Resonant Absorption: Every cell vibrates at a specific frequency. Cancer cells, with their altered DNA, have a different “signature” than healthy cells. 📍 Internal Heating: By sweeping an EM field to 450 kHz, only the cancer cells absorb energy. They heat from the inside out and disintegrate. 📍 The Result: Healthy tissue remains unaffected because it isn’t “tuned” to that frequency. It was tested, it worked, and it was buried. Why? Because a one-time frequency treatment doesn’t create the recurring revenue of chemotherapy. [h/t HarmonicEarthTheory on IG]

Ben Wehrman

115,816 görüntüleme • 2 ay önce

We (humans) evolved amid natural low-level, unpolarized ELF/geomagnetic fields and electromagnetic frequencies such as 300GHz, 300MHz or even 60Hz that can be found in sources of nnEMFs ranging from your smartphone all the way to radars and satellites. So unlike native EMFs, which occur naturally from the earth’s magnetic field or sunlight for example, nnEMFs have frequencies, intensities and patterns that differ from those our biology evolved to handle. Some key characteristics of nnEMFs include: -They are classified by frequency (measured in hertz (Hz)) -They include extremely low frequency (ELF) fields (such as 50–60 Hz from power lines), radiofrequency (RF) fields (such as 300 kHz–300 GHz, used in mobile phones and Wi-Fi) and microwave frequencies (such as 2.45 GHz in microwaves). -They (nnEMFs) are polarized and pulsed unlike natural EMFs, which are often unpolarized and continuous. Now the seven key biological mechanisms underlying the negative effects of nnEMFs include: -Oxidative stress. nnEMFs, particularly RF fields, can increase reactive oxygen species (ROS) like superoxide or hydroxyl radicals and cause lipid peroxidation in cells, thus alterling antioxidant enzyme levels (such as superoxide dismutase) and damaging cell membranes, proteins and DNA. -Calcium channel dysregulation. nnEMFs, increase intracellular calcium through voltage-gated calcium channels (VGCCs). VGCCs are large protein complexes that “open” in response to electrical signals (they open when the membrane depolarizes (becomes less negative)), in order for calcium ions to enter cells (due to its concentration gradient (higher outside than inside cells)) and nnEMFs act as an external electrical stimulus. VGCCs trigger neurotransmitter release (particularly glutamate), initiate contraction in cardiac and skeletal muscle for example, eegulate hormone secretion, control gene expression, enzyme activity and apoptosis. -DNA damage. nnEMFs, may induce single- and double-strand DNA breaks, directly (through energy transfer) or indirectly (through ROS). -Melatonin suppression. This happens possibly by altering neuronal signaling or mimicking some signals of light exposure but human and animal studies show reduced melatonin levels after RFR exposure, particularly at night. -Increasing blood-brain barrier permeability. This is well documented in animal studies that show increased blood-brain barrier leakage after RFR exposure, but it’s true that human research is limited. Yet based on the 4 previous mechanisms that were just discussed this isn’t unlikely and nnEMFs probably increase permeability of endothelial cells in barriers in humans as well, probably through oxidative stress or calcium-mediated tight junction disruption. -Autonomic nervous system dysregulation. It’s documented that nnEMFs alter sympathetic and parasympathetic activity thus affecting heart rate variability and of course, animal studies show even altered neurotransmitter levels. -Disruption of cellular electrical balance. Our cells maintain a negative membrane potential (resting potential) and nnEMFs interfere with ion channels altering membrane potential and disrupting processes like nerve signaling, muscle contraction or enzyme function. Then of course there are other ones such as heat shock protein induction for example (cell culture studies show increased HSP expression after EMF exposure, even at non-thermal levels). "Source?" The video/experiment was created by RF Safe
1:15

We (humans) evolved amid natural low-level, unpolarized ELF/geomagnetic fields and electromagnetic frequencies such as 300GHz, 300MHz or even 60Hz that can be found in sources of nnEMFs ranging from your smartphone all the way to radars and satellites. So unlike native EMFs, which occur naturally from the earth’s magnetic field or sunlight for example, nnEMFs have frequencies, intensities and patterns that differ from those our biology evolved to handle. Some key characteristics of nnEMFs include: -They are classified by frequency (measured in hertz (Hz)) -They include extremely low frequency (ELF) fields (such as 50–60 Hz from power lines), radiofrequency (RF) fields (such as 300 kHz–300 GHz, used in mobile phones and Wi-Fi) and microwave frequencies (such as 2.45 GHz in microwaves). -They (nnEMFs) are polarized and pulsed unlike natural EMFs, which are often unpolarized and continuous. Now the seven key biological mechanisms underlying the negative effects of nnEMFs include: -Oxidative stress. nnEMFs, particularly RF fields, can increase reactive oxygen species (ROS) like superoxide or hydroxyl radicals and cause lipid peroxidation in cells, thus alterling antioxidant enzyme levels (such as superoxide dismutase) and damaging cell membranes, proteins and DNA. -Calcium channel dysregulation. nnEMFs, increase intracellular calcium through voltage-gated calcium channels (VGCCs). VGCCs are large protein complexes that “open” in response to electrical signals (they open when the membrane depolarizes (becomes less negative)), in order for calcium ions to enter cells (due to its concentration gradient (higher outside than inside cells)) and nnEMFs act as an external electrical stimulus. VGCCs trigger neurotransmitter release (particularly glutamate), initiate contraction in cardiac and skeletal muscle for example, eegulate hormone secretion, control gene expression, enzyme activity and apoptosis. -DNA damage. nnEMFs, may induce single- and double-strand DNA breaks, directly (through energy transfer) or indirectly (through ROS). -Melatonin suppression. This happens possibly by altering neuronal signaling or mimicking some signals of light exposure but human and animal studies show reduced melatonin levels after RFR exposure, particularly at night. -Increasing blood-brain barrier permeability. This is well documented in animal studies that show increased blood-brain barrier leakage after RFR exposure, but it’s true that human research is limited. Yet based on the 4 previous mechanisms that were just discussed this isn’t unlikely and nnEMFs probably increase permeability of endothelial cells in barriers in humans as well, probably through oxidative stress or calcium-mediated tight junction disruption. -Autonomic nervous system dysregulation. It’s documented that nnEMFs alter sympathetic and parasympathetic activity thus affecting heart rate variability and of course, animal studies show even altered neurotransmitter levels. -Disruption of cellular electrical balance. Our cells maintain a negative membrane potential (resting potential) and nnEMFs interfere with ion channels altering membrane potential and disrupting processes like nerve signaling, muscle contraction or enzyme function. Then of course there are other ones such as heat shock protein induction for example (cell culture studies show increased HSP expression after EMF exposure, even at non-thermal levels). "Source?" The video/experiment was created by RF Safe

George Ferman

31,663 görüntüleme • 19 gün önce

🚨 WHY ARE THERE OVER 400 PUBLISHED PAPERS ON IVERMECTIN AND CANCER? Because researchers discovered something unexpected. Ivermectin doesn't just target parasites. According to preclinical research, it appears to interact with cancer cells through multiple biological pathways. One of the most discussed? 📌 Cancer Stem Cells These are the cells believed to survive treatment, remain dormant for years, and potentially contribute to recurrence and spread. According to Dr. William Makis: 💊 Chemotherapy primarily targets rapidly dividing cancer cells. 💊 Ivermectin has been studied for its potential effects on cancer stem cells. That's why some researchers believe the combination deserves attention. But that's only part of the story. Researchers have also investigated ivermectin's potential ability to: ✅ Target cancer stem cells ✅ Influence tumor signaling pathways ✅ Alter cancer cell behavior ✅ Reverse chemotherapy resistance One of the most fascinating findings involves chemotherapy resistance. Over time, some cancer cells develop the ability to push chemotherapy drugs back out of the cell. Researchers have reported that ivermectin may interfere with these resistance mechanisms, potentially making cancer cells susceptible again. And then there's Fenbendazole and Mebendazole. While Ivermectin is being studied for one set of mechanisms, Fenbendazole and Mebendazole appear to work differently. Researchers have investigated their potential ability to: 📌 Block glucose transporters on cancer cells 📌 Reduce the cell's ability to use glucose as fuel 📌 Interfere with pathways associated with tumor growth Think about that. Different compounds. Different mechanisms. The same goal. That's why scientists continue publishing study after study. Not because these compounds are a fad. Because researchers keep uncovering new biological pathways worth investigating. And that's why the conversation around Ivermectin, Fenbendazole, and Mebendazole continues to grow. 💊 If you’re looking into these drugs, check out Ivermectin, Fenbendazole, and Mebendazole from RXMEDS.STORE. #Ivermectin #Fenbendazole #Mebendazole #CancerResearch #CancerStemCells #RepurposedDrugs #CancerBiology #RxMeds
3:32

🚨 WHY ARE THERE OVER 400 PUBLISHED PAPERS ON IVERMECTIN AND CANCER? Because researchers discovered something unexpected. Ivermectin doesn't just target parasites. According to preclinical research, it appears to interact with cancer cells through multiple biological pathways. One of the most discussed? 📌 Cancer Stem Cells These are the cells believed to survive treatment, remain dormant for years, and potentially contribute to recurrence and spread. According to Dr. William Makis: 💊 Chemotherapy primarily targets rapidly dividing cancer cells. 💊 Ivermectin has been studied for its potential effects on cancer stem cells. That's why some researchers believe the combination deserves attention. But that's only part of the story. Researchers have also investigated ivermectin's potential ability to: ✅ Target cancer stem cells ✅ Influence tumor signaling pathways ✅ Alter cancer cell behavior ✅ Reverse chemotherapy resistance One of the most fascinating findings involves chemotherapy resistance. Over time, some cancer cells develop the ability to push chemotherapy drugs back out of the cell. Researchers have reported that ivermectin may interfere with these resistance mechanisms, potentially making cancer cells susceptible again. And then there's Fenbendazole and Mebendazole. While Ivermectin is being studied for one set of mechanisms, Fenbendazole and Mebendazole appear to work differently. Researchers have investigated their potential ability to: 📌 Block glucose transporters on cancer cells 📌 Reduce the cell's ability to use glucose as fuel 📌 Interfere with pathways associated with tumor growth Think about that. Different compounds. Different mechanisms. The same goal. That's why scientists continue publishing study after study. Not because these compounds are a fad. Because researchers keep uncovering new biological pathways worth investigating. And that's why the conversation around Ivermectin, Fenbendazole, and Mebendazole continues to grow. 💊 If you’re looking into these drugs, check out Ivermectin, Fenbendazole, and Mebendazole from RXMEDS.STORE. #Ivermectin #Fenbendazole #Mebendazole #CancerResearch #CancerStemCells #RepurposedDrugs #CancerBiology #RxMeds

RXMEDS.STORE

16,612 görüntüleme • 3 ay önce

Aspirin — the cheap pill sitting in your medicine cabinet — could become a powerful new tool against cancer. A March 2025 study published in Nature found that aspirin helps “unleash” T-cells in the immune system, making them more effective at hunting down and attacking cancer cells, including metastatic ones. Dr. Elisa Port, Chief of Breast Surgery at Mount Sinai, explained on CBS News that this ties into the same mechanism that makes aspirin effective at preventing blood clots and heart disease. The research builds on earlier work showing aspirin’s anti-inflammatory effects can enhance immunotherapy responses by reducing platelet-driven immune suppression. It’s still early stages (mostly animal data so far), and doctors aren’t recommending it for cancer prevention yet — but the potential is intriguing. It’s honestly wild that something so common and inexpensive might play a real role in fighting cancer. Shows how much we still have to discover about everyday medicines. If this holds up in larger human trials, it could offer a low-cost way to support cancer treatment for millions. Would you be excited or cautious if a common drug like aspirin turned out to have real anti-cancer effects?
1:27

Aspirin — the cheap pill sitting in your medicine cabinet — could become a powerful new tool against cancer. A March 2025 study published in Nature found that aspirin helps “unleash” T-cells in the immune system, making them more effective at hunting down and attacking cancer cells, including metastatic ones. Dr. Elisa Port, Chief of Breast Surgery at Mount Sinai, explained on CBS News that this ties into the same mechanism that makes aspirin effective at preventing blood clots and heart disease. The research builds on earlier work showing aspirin’s anti-inflammatory effects can enhance immunotherapy responses by reducing platelet-driven immune suppression. It’s still early stages (mostly animal data so far), and doctors aren’t recommending it for cancer prevention yet — but the potential is intriguing. It’s honestly wild that something so common and inexpensive might play a real role in fighting cancer. Shows how much we still have to discover about everyday medicines. If this holds up in larger human trials, it could offer a low-cost way to support cancer treatment for millions. Would you be excited or cautious if a common drug like aspirin turned out to have real anti-cancer effects?

Camus

29,301 görüntüleme • 4 ay önce

Anthropological immortality means that a human being continues to live in others, for his essence is not the body but a totality of qualities, actions, and ideas that arise within the common field of human life, are shaped by it, and return to it. We are all manifestations of the same material called humanity. Ethical immortality demands more: not merely to be continued, but to live a creative life — multiplying eternal values. : The author distinguishes two forms of immortality that survive the body. Anthropological immortality is the simple fact that every person continues to exist in others. A human being is never just flesh; he is the sum of qualities, actions, and ideas that emerge from the shared human field, are shaped by it, and flow back into it. We are temporary waves in the same ocean called humanity; when the wave breaks, the water remains. Ethical immortality demands far more. It is not enough to be remembered; one must live creatively, deliberately multiplying the eternal values (love, truth, beauty, justice, compassion) that outlast any single life. To achieve this is to become a conscious co-creator of humanity itself. The ordinary person leaves ripples; the ethical person carves channels that guide the river for centuries. In the end we are all made of the same material, humanity. The difference lies in whether we merely pass through it or choose to enlarge it while we are here.
0:28

Anthropological immortality means that a human being continues to live in others, for his essence is not the body but a totality of qualities, actions, and ideas that arise within the common field of human life, are shaped by it, and return to it. We are all manifestations of the same material called humanity. Ethical immortality demands more: not merely to be continued, but to live a creative life — multiplying eternal values. : The author distinguishes two forms of immortality that survive the body. Anthropological immortality is the simple fact that every person continues to exist in others. A human being is never just flesh; he is the sum of qualities, actions, and ideas that emerge from the shared human field, are shaped by it, and flow back into it. We are temporary waves in the same ocean called humanity; when the wave breaks, the water remains. Ethical immortality demands far more. It is not enough to be remembered; one must live creatively, deliberately multiplying the eternal values (love, truth, beauty, justice, compassion) that outlast any single life. To achieve this is to become a conscious co-creator of humanity itself. The ordinary person leaves ripples; the ethical person carves channels that guide the river for centuries. In the end we are all made of the same material, humanity. The difference lies in whether we merely pass through it or choose to enlarge it while we are here.

Zafar Mirzo | Quotes

306,633 görüntüleme • 9 ay önce

Changes in 24 hours from taking Ivermectin. Two Doctors. Researching the same drug. One doing lab experiments on cells. The other observing patients in real time. Lab based cell observations meets microbiome research. And a real world case study. Dr. Sabine Hazan: “Once you change something.. you give someone Vitamin C.. you give someone Ivermectin... you see the changes... our data showed that Ivermectin increases the Bifidobacteria within 24 hours” Dr. Kylie Wagstaff: “It does exactly that.. in cells growing in a dish, in the laboratory... we’re able to stop the virus from replicating within about 24-48 hours” Those two research ideas collide in a real world case study Dr. Hazan witnessed: “One of my patients crashed... he’s on his way to the hospital... this was the rise of oxygen with giving Ivermectin” Interestingly... Ivermectin is a fermented product of a bacteria “in the same group of microbes that share one thing in common as Bifidobacteria.”... which means that several mechanistic ideas give extra perspective on this Nobel Prize winning anti parasitic drug. Is the microbiome or other pharmacokinetics at play here?
4:30

Changes in 24 hours from taking Ivermectin. Two Doctors. Researching the same drug. One doing lab experiments on cells. The other observing patients in real time. Lab based cell observations meets microbiome research. And a real world case study. Dr. Sabine Hazan: “Once you change something.. you give someone Vitamin C.. you give someone Ivermectin... you see the changes... our data showed that Ivermectin increases the Bifidobacteria within 24 hours” Dr. Kylie Wagstaff: “It does exactly that.. in cells growing in a dish, in the laboratory... we’re able to stop the virus from replicating within about 24-48 hours” Those two research ideas collide in a real world case study Dr. Hazan witnessed: “One of my patients crashed... he’s on his way to the hospital... this was the rise of oxygen with giving Ivermectin” Interestingly... Ivermectin is a fermented product of a bacteria “in the same group of microbes that share one thing in common as Bifidobacteria.”... which means that several mechanistic ideas give extra perspective on this Nobel Prize winning anti parasitic drug. Is the microbiome or other pharmacokinetics at play here?

Joe Tippens

17,886 görüntüleme • 4 ay önce

The Dangerous Cult of 'Fasting' Influencers. Fasting has its anecdotal benefits, yes. But it is overrated. And water fasting is highly overrated. But this video featuring a Cardiologist is amusingly nonsense. There is no study from Boston (from a "University?" - how vague!) that says 7-days water fasting reduces risk of cancer (what cancer?) by 70%. And there is no proof that fasting kills cancer cells in humans. Here is what fasting does to cancers in humans. Nothing. Fasting is now become a sort of religion-like cult for wellness influencers to rake in views and engagement. From a scientific standpoint, there are no realistically good human studies to prove anything from fasting that benefits cancers. I know, I know, "autophagy" and all that. Autophagy: Autophagy is the natural, conserved degradation of the cell that removes unnecessary or dysfunctional components. Yes, its a legit term and all. But in the context of cancer reduction and fasting in humans, it sounds like "immunity boosting," another wellness fraud term. The effects of fasting on cancer cells are all based on MOUSE studies, and none explicitly translated to humans. See this paper: everything is based on cells and tissues and small animal experiments: "While research on the subject is tantalizing, there’s little clinical evidence involving humans to substantiate the claims. Studies on the potential impacts on cancer treatment from various forms of fasting or calorie restriction, including the possibility that they reduce side effects, have been limited." "Fasting may not be appropriate for malnourished individuals or those with cancer cachexia, which results in a continuing loss of skeletal muscle mass, or for people with chronic diseases. Those with diabetes need to be very careful, because of the risk of hypoglycemia." "Based on our systematic review and meta-analysis, there is currently no evidence supporting the superiority of therapeutic fasting over non-fasting in preventing chemotherapy toxicity." - see here: Even intermittent fasting (IF) is overrated in cancer. "IF may be considered in adults seeking cancer-prevention benefits through means of weight management, butwhether IF itself affects cancer-related metabolic and molecular pathways remains unanswered. See here: Also this: "Fasting for short periods does not have any beneficial effect on the quality of life of cancer patients during treatment. Evidence on fasting regimes reducing side effects and toxicities of chemotherapy is missing." See here: The whole aspect of "fasting reducing cancer incidence" in the real world is just due to weight loss. Obesity is associated with at least 13 types of cancers and reversing obesity reduces risk of cancer - nothing to do with fasting killing off cancers cells in the body. And one can lose weight even without fasting. See here: Everything from prevention of adverse events of cancer, to reduction in side effects from chemotherapy, to slowing cancer growth by reducing glucose levels, to promoting cell regeneration by affecting autophagy is all LAB BASED MOLECULAR LEVEL HYPOTHESIS that has not been proven conclusively in humans. See here: Cancer patients must not starve. They must remain hydrated and they must eat a well balanced diet because cancer condition is highly demanding. And dont water fast for 7 days. Easy for people to make reels on it, but in real life, it may prove disastrous. Water fast does make you lose weight (because of starvation) but it is not at all a healthy way to lose weight. Stop with this fasting and cancer madness already.
0:21

The Dangerous Cult of 'Fasting' Influencers. Fasting has its anecdotal benefits, yes. But it is overrated. And water fasting is highly overrated. But this video featuring a Cardiologist is amusingly nonsense. There is no study from Boston (from a "University?" - how vague!) that says 7-days water fasting reduces risk of cancer (what cancer?) by 70%. And there is no proof that fasting kills cancer cells in humans. Here is what fasting does to cancers in humans. Nothing. Fasting is now become a sort of religion-like cult for wellness influencers to rake in views and engagement. From a scientific standpoint, there are no realistically good human studies to prove anything from fasting that benefits cancers. I know, I know, "autophagy" and all that. Autophagy: Autophagy is the natural, conserved degradation of the cell that removes unnecessary or dysfunctional components. Yes, its a legit term and all. But in the context of cancer reduction and fasting in humans, it sounds like "immunity boosting," another wellness fraud term. The effects of fasting on cancer cells are all based on MOUSE studies, and none explicitly translated to humans. See this paper: everything is based on cells and tissues and small animal experiments: "While research on the subject is tantalizing, there’s little clinical evidence involving humans to substantiate the claims. Studies on the potential impacts on cancer treatment from various forms of fasting or calorie restriction, including the possibility that they reduce side effects, have been limited." "Fasting may not be appropriate for malnourished individuals or those with cancer cachexia, which results in a continuing loss of skeletal muscle mass, or for people with chronic diseases. Those with diabetes need to be very careful, because of the risk of hypoglycemia." "Based on our systematic review and meta-analysis, there is currently no evidence supporting the superiority of therapeutic fasting over non-fasting in preventing chemotherapy toxicity." - see here: Even intermittent fasting (IF) is overrated in cancer. "IF may be considered in adults seeking cancer-prevention benefits through means of weight management, butwhether IF itself affects cancer-related metabolic and molecular pathways remains unanswered. See here: Also this: "Fasting for short periods does not have any beneficial effect on the quality of life of cancer patients during treatment. Evidence on fasting regimes reducing side effects and toxicities of chemotherapy is missing." See here: The whole aspect of "fasting reducing cancer incidence" in the real world is just due to weight loss. Obesity is associated with at least 13 types of cancers and reversing obesity reduces risk of cancer - nothing to do with fasting killing off cancers cells in the body. And one can lose weight even without fasting. See here: Everything from prevention of adverse events of cancer, to reduction in side effects from chemotherapy, to slowing cancer growth by reducing glucose levels, to promoting cell regeneration by affecting autophagy is all LAB BASED MOLECULAR LEVEL HYPOTHESIS that has not been proven conclusively in humans. See here: Cancer patients must not starve. They must remain hydrated and they must eat a well balanced diet because cancer condition is highly demanding. And dont water fast for 7 days. Easy for people to make reels on it, but in real life, it may prove disastrous. Water fast does make you lose weight (because of starvation) but it is not at all a healthy way to lose weight. Stop with this fasting and cancer madness already.

TheLiverDoc™

269,527 görüntüleme • 2 yıl önce

Evolution says you can turn anything into anything if you tweak it long enough. But that house of cards collapses immediately when you realize what it takes to make even a single cell. They say new cell types arise one mutation at a time. Is that plausible? Here is the issue: Different cell types are created through a massive coordinated stack of genetic information, and it's not all just about DNA sequences. First you need a whole suite of new genetic systems related to the cell: new genes for the cell’s internal systems, instructions for its specific functional role in the body, the regulators that coordinate everything, markers to tell them where to go and when, and the controls that keep the wrong programs off. But the DNA structure itself must also be manipulated. You see, every cell in your body contains the DNA instructions to make any other cell. So how does a bone cell become a bone cell instead of a skin cell? Because of how the DNA is folded. DNA is folded in certain ways for different cell types, so that only the "bone cell instructions" are able to be read by the "cell construction program." The DNA fold decides which programs are open for each cell type. This is critical. If DNA is not folded properly so that specific cell-type information can be read, catastrophe ensues. Then you need placement blueprints, so the cells form in the right place, in the right number, and lock together to form a functional tissue. These developmental instructions are passed from parent to offspring - but research shows that tweaking these master developmental programs ends badly for the child. One mutation at a time cannot invent that entire programming stack and keep it coordinated. Research has confirmed this. To convert one cell type into another in the lab, researchers have to force many changes to happen at the same time in coordination. And even when directed by the researcher, cell conversion almost always fails. Change the sequence without the fold and you cannot get a new cell type. Fold the DNA without the new systems and you can only rearrange old programs. Make the cell without the map and it shows up in the wrong place. Break one layer in the stack and the others do not patiently wait - they fail. So creating a new cell type is not simply "tweak a gene one at a time." It requires a coordinated stack of entirely new programmed instructions: > New suite of internal systems, programmed into the DNA > New functional DNA fold so only the right systems are activated > New mapping blueprints so everything goes where it's needed Step-by-step mutation does not coordinate those layers. It produces broken cells before it produces new ones. Coordination of this level of complexity has only ever been known to come from one place: Intelligence.
0:29

Evolution says you can turn anything into anything if you tweak it long enough. But that house of cards collapses immediately when you realize what it takes to make even a single cell. They say new cell types arise one mutation at a time. Is that plausible? Here is the issue: Different cell types are created through a massive coordinated stack of genetic information, and it's not all just about DNA sequences. First you need a whole suite of new genetic systems related to the cell: new genes for the cell’s internal systems, instructions for its specific functional role in the body, the regulators that coordinate everything, markers to tell them where to go and when, and the controls that keep the wrong programs off. But the DNA structure itself must also be manipulated. You see, every cell in your body contains the DNA instructions to make any other cell. So how does a bone cell become a bone cell instead of a skin cell? Because of how the DNA is folded. DNA is folded in certain ways for different cell types, so that only the "bone cell instructions" are able to be read by the "cell construction program." The DNA fold decides which programs are open for each cell type. This is critical. If DNA is not folded properly so that specific cell-type information can be read, catastrophe ensues. Then you need placement blueprints, so the cells form in the right place, in the right number, and lock together to form a functional tissue. These developmental instructions are passed from parent to offspring - but research shows that tweaking these master developmental programs ends badly for the child. One mutation at a time cannot invent that entire programming stack and keep it coordinated. Research has confirmed this. To convert one cell type into another in the lab, researchers have to force many changes to happen at the same time in coordination. And even when directed by the researcher, cell conversion almost always fails. Change the sequence without the fold and you cannot get a new cell type. Fold the DNA without the new systems and you can only rearrange old programs. Make the cell without the map and it shows up in the wrong place. Break one layer in the stack and the others do not patiently wait - they fail. So creating a new cell type is not simply "tweak a gene one at a time." It requires a coordinated stack of entirely new programmed instructions: > New suite of internal systems, programmed into the DNA > New functional DNA fold so only the right systems are activated > New mapping blueprints so everything goes where it's needed Step-by-step mutation does not coordinate those layers. It produces broken cells before it produces new ones. Coordination of this level of complexity has only ever been known to come from one place: Intelligence.

Divinely Designed

22,570 görüntüleme • 20 gün önce

Deuterium — a variable almost nobody tracks — regulates cell growth and mitochondrial function. It sits upstream of cancer and everything downstream. Your mitochondria maintain a lower deuterium concentration inside their inner membrane than outside. That gradient is not incidental. It's a feature of normal mitochondrial function. Roman Zubarev — professor of medical proteomics at the Karolinska Institute, trained at Moscow's elite physics institute — has spent years studying what happens when you disturb it. 1. Deuterium As A Cell Growth Regulator Deuterium — heavy hydrogen — regulates cell growth rate in the range of approximately 30–350 ppm. Earth's normal deuterium concentration is around 150 ppm. When cells are deprived of this normal amount, their growth slows down. To test this, Zubarev’s lab used A549 lung cancer cells — currently the most widely used cell line in biology — and exposed them to deuterium-depleted water at about 80 ppm. The result? Cancer cell growth rate dropped by 30%. Once deuterium concentrations step outside of that 30–350 ppm regulatory window, the effects stop being regulatory and start becoming highly detrimental. For example Mars carries approximately 750–1,050 ppm of deuterium—roughly 5 to 7 times Earth's natural concentration. When terrestrial organisms are exposed to Martian deuterium levels, they show significant survival decline. Zubarev’s team conducted a two-year experiment growing small shrimp in isolated environments where the water was modified to contain ~600 ppm of deuterium. They found that the survival rates of the shrimp significantly declined compared to those grown in normal water. 2. The Mitochondrial Mechanism — How Deuterium Depleted Water (DDW) Actually Works Alongside the well-known proton gradient, there is also a deuterium gradient across the inner mitochondrial membrane. Normally, the concentration of deuterium is lower inside the membrane than it is outside. Mitochondrial lipids are naturally deuterium-depleted. When cells are placed in 80 ppm deuterium-depleted water — lower than the normal ~150 ppm outside — the gradient reverses. More deuterium inside the membrane than outside. So how does this reversal suppress growth? This reversal upsets reactive oxygen species (ROS) production. To try and restore equilibrium, the mitochondria rapidly increase their production of ROS. This sudden spike in ROS induces oxidative stress within the cell, which the researchers identified as the primary molecular mechanism that ultimately suppresses the growth of the cells. This is the anti-cancer mechanism. Zubarev: "We have not invented this mechanism — it's very well known." To prove that DDW suppresses cancer cell growth by inducing oxidative stress they added NAC — N-acetylcysteine, a standard antioxidant — to DDW-treated cancer cells. If DDW works through ROS, an antioxidant should cancel the effect. The result? At approximately 2 millimolar NAC, the DDW anti-cancer effect was statistically eliminated. Then they tested the reverse. They combined DDW with auranofin — a drug that induces oxidative stress. If both work through ROS, combining them should produce synergistic effect. The result? At low to medium concentrations, adding the drug to the DDW created a "double whammy effect" where the cell count went down even further. However, at very high concentrations of the drug, the effect of the DDW diminished, which Zubarev explains makes sense because a cell does not need two overwhelming sources of reactive oxygen species to die. Three-layer validation. Published in Molecular and Cellular Proteomics — the top proteomics journal. 3. The Antioxidant Implication Standard health messaging treats ROS as purely bad. Antioxidants good. Oxidative stress bad. Zubarev's data complicates this directly. DDW works by increasing ROS in cancer cells. Antioxidants statistically cancelled the therapeutic effect. Auranofin — an oxidative stress inducer — synergized with DDW against cancer. Important caveat: this finding is in cancer cells, not in healthy humans. Zubarev notes that normal human cells react differently, stating that normal human cells are much less sensitive to DDW. Therefore, the induction of ROS to slow down growth is a therapeutic mechanism specifically observed in fast-growing cancer cells, not a general effect reported for healthy cells. But the blanket "antioxidants are good" narrative fails here. Context determines whether ROS is friend or enemy. 4. You Are Not What You Eat The standard model of nutrition assumes the body passively absorbs its dietary inputs — including isotopic composition. Zubarev's data shows the opposite. The body actively resists changes to its internal isotopic composition. It defends a specific ratio the way it defends pH or temperature. Isotopes modulate their own fractionation — the biological system selectively processes and separates heavy and light isotopes to maintain equilibrium. The isotopic quality of what you eat and drink is a regulated biological input — not a passive one. For example, the deuterium levels found in the proline, hydroxyproline, and collagen of seals are twice as high as the deuterium levels in the surrounding seawater. Because the isotopic concentration in the seals' biological building blocks is double that of their environment, there is no way to attribute this composition simply to their food. 5. Isotopic Resonance — The Order Underlying Life Plot the isotopic masses and abundances of the elements that make up biological molecules — hydrogen, carbon, nitrogen, oxygen. You'd expect random scatter, a scattered "galaxy" of dots. Instead you find a precise line. Zubarev calls it isotopic resonance. At natural isotopic abundances, biological molecules cluster in a specific ratio that produces the simplest, most efficient molecular conformations. That ratio is the point at which life's chemistry runs fastest. The probability of this pattern appearing by chance is astronomically small. Zubarev — a physicist trained in probability — cannot dismiss it: "This is the line of God, if you want." Life doesn't exist here just because of liquid water and moderate temperature. It exists here because Earth's isotopic composition happens to hit the resonance at which life's machinery runs. Disturb that composition — and the system works to defend it. The isotopic quality of your water, your food, and your environment is not a background variable. It is the upstream input everything else depends on.
3:59

Deuterium — a variable almost nobody tracks — regulates cell growth and mitochondrial function. It sits upstream of cancer and everything downstream. Your mitochondria maintain a lower deuterium concentration inside their inner membrane than outside. That gradient is not incidental. It's a feature of normal mitochondrial function. Roman Zubarev — professor of medical proteomics at the Karolinska Institute, trained at Moscow's elite physics institute — has spent years studying what happens when you disturb it. 1. Deuterium As A Cell Growth Regulator Deuterium — heavy hydrogen — regulates cell growth rate in the range of approximately 30–350 ppm. Earth's normal deuterium concentration is around 150 ppm. When cells are deprived of this normal amount, their growth slows down. To test this, Zubarev’s lab used A549 lung cancer cells — currently the most widely used cell line in biology — and exposed them to deuterium-depleted water at about 80 ppm. The result? Cancer cell growth rate dropped by 30%. Once deuterium concentrations step outside of that 30–350 ppm regulatory window, the effects stop being regulatory and start becoming highly detrimental. For example Mars carries approximately 750–1,050 ppm of deuterium—roughly 5 to 7 times Earth's natural concentration. When terrestrial organisms are exposed to Martian deuterium levels, they show significant survival decline. Zubarev’s team conducted a two-year experiment growing small shrimp in isolated environments where the water was modified to contain ~600 ppm of deuterium. They found that the survival rates of the shrimp significantly declined compared to those grown in normal water. 2. The Mitochondrial Mechanism — How Deuterium Depleted Water (DDW) Actually Works Alongside the well-known proton gradient, there is also a deuterium gradient across the inner mitochondrial membrane. Normally, the concentration of deuterium is lower inside the membrane than it is outside. Mitochondrial lipids are naturally deuterium-depleted. When cells are placed in 80 ppm deuterium-depleted water — lower than the normal ~150 ppm outside — the gradient reverses. More deuterium inside the membrane than outside. So how does this reversal suppress growth? This reversal upsets reactive oxygen species (ROS) production. To try and restore equilibrium, the mitochondria rapidly increase their production of ROS. This sudden spike in ROS induces oxidative stress within the cell, which the researchers identified as the primary molecular mechanism that ultimately suppresses the growth of the cells. This is the anti-cancer mechanism. Zubarev: "We have not invented this mechanism — it's very well known." To prove that DDW suppresses cancer cell growth by inducing oxidative stress they added NAC — N-acetylcysteine, a standard antioxidant — to DDW-treated cancer cells. If DDW works through ROS, an antioxidant should cancel the effect. The result? At approximately 2 millimolar NAC, the DDW anti-cancer effect was statistically eliminated. Then they tested the reverse. They combined DDW with auranofin — a drug that induces oxidative stress. If both work through ROS, combining them should produce synergistic effect. The result? At low to medium concentrations, adding the drug to the DDW created a "double whammy effect" where the cell count went down even further. However, at very high concentrations of the drug, the effect of the DDW diminished, which Zubarev explains makes sense because a cell does not need two overwhelming sources of reactive oxygen species to die. Three-layer validation. Published in Molecular and Cellular Proteomics — the top proteomics journal. 3. The Antioxidant Implication Standard health messaging treats ROS as purely bad. Antioxidants good. Oxidative stress bad. Zubarev's data complicates this directly. DDW works by increasing ROS in cancer cells. Antioxidants statistically cancelled the therapeutic effect. Auranofin — an oxidative stress inducer — synergized with DDW against cancer. Important caveat: this finding is in cancer cells, not in healthy humans. Zubarev notes that normal human cells react differently, stating that normal human cells are much less sensitive to DDW. Therefore, the induction of ROS to slow down growth is a therapeutic mechanism specifically observed in fast-growing cancer cells, not a general effect reported for healthy cells. But the blanket "antioxidants are good" narrative fails here. Context determines whether ROS is friend or enemy. 4. You Are Not What You Eat The standard model of nutrition assumes the body passively absorbs its dietary inputs — including isotopic composition. Zubarev's data shows the opposite. The body actively resists changes to its internal isotopic composition. It defends a specific ratio the way it defends pH or temperature. Isotopes modulate their own fractionation — the biological system selectively processes and separates heavy and light isotopes to maintain equilibrium. The isotopic quality of what you eat and drink is a regulated biological input — not a passive one. For example, the deuterium levels found in the proline, hydroxyproline, and collagen of seals are twice as high as the deuterium levels in the surrounding seawater. Because the isotopic concentration in the seals' biological building blocks is double that of their environment, there is no way to attribute this composition simply to their food. 5. Isotopic Resonance — The Order Underlying Life Plot the isotopic masses and abundances of the elements that make up biological molecules — hydrogen, carbon, nitrogen, oxygen. You'd expect random scatter, a scattered "galaxy" of dots. Instead you find a precise line. Zubarev calls it isotopic resonance. At natural isotopic abundances, biological molecules cluster in a specific ratio that produces the simplest, most efficient molecular conformations. That ratio is the point at which life's chemistry runs fastest. The probability of this pattern appearing by chance is astronomically small. Zubarev — a physicist trained in probability — cannot dismiss it: "This is the line of God, if you want." Life doesn't exist here just because of liquid water and moderate temperature. It exists here because Earth's isotopic composition happens to hit the resonance at which life's machinery runs. Disturb that composition — and the system works to defend it. The isotopic quality of your water, your food, and your environment is not a background variable. It is the upstream input everything else depends on.

no.mind

29,918 görüntüleme • 3 ay önce

🧬 The Recipe: How One Ovarian Cancer Trial Rebuilds the Immune System the Disease Switched Off A node-by-node case for durable immunity in the cancer that has resisted checkpoint blockade $NWBO and its #DCVax dendritic-cell platform sit at the heart of a new front-line #OvarianCancer trial, the same instructor-cell technology now aimed at the cancer that checkpoint blockade has barely touched. Advanced ovarian cancer kills more women than any other gynecologic malignancy, and it has shrugged off the #immunotherapy revolution almost entirely. Checkpoint blockade on its own reaches an objective response rate near eight percent in this disease, the figure from the $MRK #KEYNOTE-100 trial. The tumors are cold, the mutational burden is low, and the peritoneal cavity is a suppressive field that shuts an immune attack down before it can start. Two decades of single-agent vaccines and single-agent checkpoint drugs have not changed the survival math. Most patients respond to first-line chemotherapy and then relapse, and once the disease returns, the odds turn hard against them. For the patient living that diagnosis, a durable response is the only outcome that counts, and that is the one thing the field has not delivered. A Phase 2 trial opening at #UPMC Hillman in the second half of 2026, #NCT07634094, takes a different route. It does not add one more drug to the pile and hope. It treats ovarian cancer as one clinical face of a single, definable failure, and it rebuilds the broken machinery one node at a time. The sponsors are Pawel Kalinski MD PhD, $NWBO and $AIM. Here is the full logic, and why it is built to produce a response that lasts. 🔒 The hidden lesion: a silencing cascade Ovarian tumors run a self-reinforcing program that switches off the immune system's command center. It starts with chronic inflammation. Senescence-associated secretions and prostaglandin E2, the product of the COX-2 enzyme, keep the signaling protein STAT3 locked on. Persistent STAT3 pulls the silencing enzymes DNMT1 and EZH2 onto a single master gene, IRF8. That gene is the identity switch for the type 1 conventional dendritic cell, the cDC1, the one cell that licenses killer T cells with bioactive Silence IRF8 and the instructor disappears. With it gone, the tumor secretes decoy chemokines that recruit regulatory T cells, killer cells never receive their orders, and the disease grows in immunological darkness. This is not a quirk of ovarian cancer. The same cascade shows up in chronic infection and in aging tissue. Ovarian cancer is one face of a convergent mechanism, which is why a fix that works here points well beyond it. 🔄 The recipe: the cascade run in reverse Every component of the regimen corrects one node of that cascade. Pull out any single arm and the suppression reasserts itself through the others. That is what separates this from a kitchen sink: each part is load-bearing. · Celecoxib lifts the upstream PGE2 brake that keeps the silencing signal switched on. · Autologous, tumor-loaded alpha-DC1 supplies the instructor function from outside the silencing field, loaded with the whole tumor. This is the rebuilt command center the disease erased. · #rintatolimod, the selective TLR3 agonist marketed as #Ampligen, plus interferon-alpha flips the chemokine code tumor-selectively, from the CCL22 that recruits regulatory cells to the CXCL10 and CCL5 that pull in killers. #Bioferon · The alpha-DC1 program imprints CXCR3 and CCR5 homing receptors on the instructed CD8 cells, so they reach the tumor instead of circulating uselessly. · Cisplatin raises stress ligands so the killers can destroy low-antigen escape variants through the DNAM-1 and NKG2D receptors, closing the door on the engine of recurrence. · Paclitaxel plus the interferons repolarize suppressive M2 macrophages back to the supportive M1 state. · $MRK #Keytruda, releases the PD-1 brake last, only after the tumor has been made hot. The order is not cosmetic. The checkpoint comes last for a reason that most combination trials get wrong. 🔗 Why the combination is required, not additive Checkpoint blockade does not activate killer T cells by itself. Published work shows that anti-PD-1 efficacy depends on dendritic cells producing IL-12 inside the tumor (Garris, Immunity 2018). If the instructor is silenced and no IL-12 is being made, pembrolizumab has nothing to set loose. It is releasing a brake on a car with no engine. So restoring the IL-12 signal is the precondition for the checkpoint to do anything in this disease, not an optional add-on to it. The alpha-DC1 vaccine rebuilds the engine. Pembrolizumab takes the brake off. Neither delivers without the other. The relationship is causal, and that is the single idea the whole regimen is organized around. ⏳ Why the response should last A response that fades is not a cure, and durability is engineered here on four fronts at once. · Breadth. The vaccine is loaded with the whole tumor, not a single antigen, so the immune system learns the entire target and the tumor cannot escape by dropping one marker. · A lowered killing threshold. The DNAM-1 and NKG2D signals let killers finish variants that have shed antigen, while the requirement for true tumor recognition is preserved, so normal tissue is passed over. · Memory programming. Bioactive IL-12p70 does what ordinary dendritic-cell expansion cannot. It programs a self-renewing, TCF1-positive stem-like CD8 reservoir, the very population that predicts lasting benefit from checkpoint blockade (Goswami, Clinical Cancer Research 2025). · A self-reinforcing organ. Restored type 1 signaling matures tertiary lymphoid structures inside the tumor, the local factories from which durable immunity is rebuilt long after the last dose. 📊 Already partly de-risked This is not a first guess. The chemokine-and-checkpoint backbone was already tested in recurrent platinum-sensitive ovarian cancer in trial NCT03734692: intraperitoneal cisplatin plus rintatolimod plus pembrolizumab. That study produced an objective response rate near fifty percent, several times the roughly eight percent checkpoint blockade reaches alone in $MRK #KEYNOTE-100, accompanied by the exact chemokine shift the model predicts, the rise in CXCL9, CXCL10, and CXCL11 that a restored type 1 program produces. $MRK collaborated on it and supported it, and the final primary endpoint reported in May 2026. #SITC26 #ASCO26 The new trial adds the missing piece, the alpha-DC1 instructor whose intellectual property traces to #RoswellPark, and moves the whole regimen to the front line, where the tumor is largest and the antigen supply is richest. It is the same spine, established in recurrent disease, now armed with the one component that was absent. 🔬 A trial built to be read, not just won NCT07634094 enrolls twenty-eight patients with Stage III to IV epithelial ovarian, tubal, or peritoneal cancer, chemo-naive, in the neoadjuvant #neoadjuvant setting. #OvarianCancerAwareness #gyncsm #BRCA Treating before surgery buys the cleanest possible readout: the resected tumor itself. The co-primary endpoints are the safety of the full combination and pathologic complete response at debulking. A pathologic complete response, meaning no viable tumor left in the surgical specimen, is one of the most demanding endpoints in solid-tumor #oncology and a recognized marker of long-term benefit. The design also reads the mechanism directly. It looks for the chemokine switch, the rise in intratumoral CD8 cells with a favorable ratio to regulatory cells and a TCF1-positive phenotype, the falling inflammatory tone, and the specific signature of restored pulsed IL-12p70 against preserved bulk IL-12. The study is built to show whether the mechanism engaged, not only whether tumors shrank. Enrollment is expected to begin in the second half of 2026, and because the central readout is the surgical specimen rather than years of follow-up, the first mechanistic signals should arrive relatively early. 🏭 Why this is a platform, not a one-off The instructor cell at the center of this regimen is the same dendritic-cell platform Northwest Biotherapeutics has built its company around. #DCVax extended survival in Phase 3 glioblastoma (JAMA Oncology, 2023), and a UK marketing application is pending with MHRAgovuk. The same approach has already worked in ovarian cancer. At the University of Pennsylvania, a personalized whole-tumor dendritic-cell vaccine in recurrent ovarian cancer was well tolerated and induced broad antitumor T-cell responses that tracked with significantly longer survival, with two-year survival of one hundred percent in the immune responders against twenty-five percent in non-responders (Tanyi et al., Science Translational Medicine, 2018). Those dendritic cells were loaded with the patient's own whole tumor and activated toward the same type 1 program this regimen rebuilds. That is the proof of principle, and this trial is the more complete version of it. The dendritic cell here is engineered for higher, sustained IL-12p70. It is given in the front line, where the antigen supply is richest, rather than in heavily pretreated relapse. The suppressive microenvironment is reprogrammed in parallel rather than left intact, and the checkpoint is released at the end. The Penn vaccine carried the immune response largely on its own. This regimen clears the field for it first, then takes the brake off. The historical knock on personalized cell therapy was manufacturing: bespoke, hand-built, hard to scale. Northwest Biotherapeutics has been answering that directly. #Flaskworks #EDEN, the closed, automated manufacturing system the company acquired, standardizes production and removes the single-site hand manufacturing that limited earlier programs. The Sawston facility #Sawston in the UK, operated by #AdventBioServices, a wholly owned Northwest Biotherapeutics subsidiary, under MHRA good-manufacturing standards, is bringing its first Grade C suite online in 2026, a step anticipated to more than double capacity, with a dedicated leukapheresis clinic already running. The company has also added senior leadership to drive the platform, naming the biopharmaceutical veteran Dr. Annalisa Jenkins as a strategic adviser. The consequence is concrete. If the mechanism reads out in the resected tumor, the system that delivers it is already being built to scale, across the many solid tumors that run the same silencing cascade. One trial, read correctly, does not validate a single drug. It tests a repeatable way of rebuilding antitumor immunity. That reach is the point. The same instructor sits at the center of the silencing cascade across most solid tumors, which is why the dendritic-cell platform is framed around the approach itself rather than a single indication. A front-line ovarian readout that confirms the mechanism would be evidence for the method, not for one tumor type alone. The needle moves on the tissue, not on the thesis, and no paragraph substitutes for the pathology report. What the design offers is a complete, testable mechanism for durable immunity in ovarian cancer, paired with a manufacturing system already capable of producing it at scale. The readout in the resected tumor will speak for itself. Not financial advice. Do your own research. #DCVaxForBraelyn
7:34

🧬 The Recipe: How One Ovarian Cancer Trial Rebuilds the Immune System the Disease Switched Off A node-by-node case for durable immunity in the cancer that has resisted checkpoint blockade $NWBO and its #DCVax dendritic-cell platform sit at the heart of a new front-line #OvarianCancer trial, the same instructor-cell technology now aimed at the cancer that checkpoint blockade has barely touched. Advanced ovarian cancer kills more women than any other gynecologic malignancy, and it has shrugged off the #immunotherapy revolution almost entirely. Checkpoint blockade on its own reaches an objective response rate near eight percent in this disease, the figure from the $MRK #KEYNOTE-100 trial. The tumors are cold, the mutational burden is low, and the peritoneal cavity is a suppressive field that shuts an immune attack down before it can start. Two decades of single-agent vaccines and single-agent checkpoint drugs have not changed the survival math. Most patients respond to first-line chemotherapy and then relapse, and once the disease returns, the odds turn hard against them. For the patient living that diagnosis, a durable response is the only outcome that counts, and that is the one thing the field has not delivered. A Phase 2 trial opening at #UPMC Hillman in the second half of 2026, #NCT07634094, takes a different route. It does not add one more drug to the pile and hope. It treats ovarian cancer as one clinical face of a single, definable failure, and it rebuilds the broken machinery one node at a time. The sponsors are Pawel Kalinski MD PhD, $NWBO and $AIM. Here is the full logic, and why it is built to produce a response that lasts. 🔒 The hidden lesion: a silencing cascade Ovarian tumors run a self-reinforcing program that switches off the immune system's command center. It starts with chronic inflammation. Senescence-associated secretions and prostaglandin E2, the product of the COX-2 enzyme, keep the signaling protein STAT3 locked on. Persistent STAT3 pulls the silencing enzymes DNMT1 and EZH2 onto a single master gene, IRF8. That gene is the identity switch for the type 1 conventional dendritic cell, the cDC1, the one cell that licenses killer T cells with bioactive Silence IRF8 and the instructor disappears. With it gone, the tumor secretes decoy chemokines that recruit regulatory T cells, killer cells never receive their orders, and the disease grows in immunological darkness. This is not a quirk of ovarian cancer. The same cascade shows up in chronic infection and in aging tissue. Ovarian cancer is one face of a convergent mechanism, which is why a fix that works here points well beyond it. 🔄 The recipe: the cascade run in reverse Every component of the regimen corrects one node of that cascade. Pull out any single arm and the suppression reasserts itself through the others. That is what separates this from a kitchen sink: each part is load-bearing. · Celecoxib lifts the upstream PGE2 brake that keeps the silencing signal switched on. · Autologous, tumor-loaded alpha-DC1 supplies the instructor function from outside the silencing field, loaded with the whole tumor. This is the rebuilt command center the disease erased. · #rintatolimod, the selective TLR3 agonist marketed as #Ampligen, plus interferon-alpha flips the chemokine code tumor-selectively, from the CCL22 that recruits regulatory cells to the CXCL10 and CCL5 that pull in killers. #Bioferon · The alpha-DC1 program imprints CXCR3 and CCR5 homing receptors on the instructed CD8 cells, so they reach the tumor instead of circulating uselessly. · Cisplatin raises stress ligands so the killers can destroy low-antigen escape variants through the DNAM-1 and NKG2D receptors, closing the door on the engine of recurrence. · Paclitaxel plus the interferons repolarize suppressive M2 macrophages back to the supportive M1 state. · $MRK #Keytruda, releases the PD-1 brake last, only after the tumor has been made hot. The order is not cosmetic. The checkpoint comes last for a reason that most combination trials get wrong. 🔗 Why the combination is required, not additive Checkpoint blockade does not activate killer T cells by itself. Published work shows that anti-PD-1 efficacy depends on dendritic cells producing IL-12 inside the tumor (Garris, Immunity 2018). If the instructor is silenced and no IL-12 is being made, pembrolizumab has nothing to set loose. It is releasing a brake on a car with no engine. So restoring the IL-12 signal is the precondition for the checkpoint to do anything in this disease, not an optional add-on to it. The alpha-DC1 vaccine rebuilds the engine. Pembrolizumab takes the brake off. Neither delivers without the other. The relationship is causal, and that is the single idea the whole regimen is organized around. ⏳ Why the response should last A response that fades is not a cure, and durability is engineered here on four fronts at once. · Breadth. The vaccine is loaded with the whole tumor, not a single antigen, so the immune system learns the entire target and the tumor cannot escape by dropping one marker. · A lowered killing threshold. The DNAM-1 and NKG2D signals let killers finish variants that have shed antigen, while the requirement for true tumor recognition is preserved, so normal tissue is passed over. · Memory programming. Bioactive IL-12p70 does what ordinary dendritic-cell expansion cannot. It programs a self-renewing, TCF1-positive stem-like CD8 reservoir, the very population that predicts lasting benefit from checkpoint blockade (Goswami, Clinical Cancer Research 2025). · A self-reinforcing organ. Restored type 1 signaling matures tertiary lymphoid structures inside the tumor, the local factories from which durable immunity is rebuilt long after the last dose. 📊 Already partly de-risked This is not a first guess. The chemokine-and-checkpoint backbone was already tested in recurrent platinum-sensitive ovarian cancer in trial NCT03734692: intraperitoneal cisplatin plus rintatolimod plus pembrolizumab. That study produced an objective response rate near fifty percent, several times the roughly eight percent checkpoint blockade reaches alone in $MRK #KEYNOTE-100, accompanied by the exact chemokine shift the model predicts, the rise in CXCL9, CXCL10, and CXCL11 that a restored type 1 program produces. $MRK collaborated on it and supported it, and the final primary endpoint reported in May 2026. #SITC26 #ASCO26 The new trial adds the missing piece, the alpha-DC1 instructor whose intellectual property traces to #RoswellPark, and moves the whole regimen to the front line, where the tumor is largest and the antigen supply is richest. It is the same spine, established in recurrent disease, now armed with the one component that was absent. 🔬 A trial built to be read, not just won NCT07634094 enrolls twenty-eight patients with Stage III to IV epithelial ovarian, tubal, or peritoneal cancer, chemo-naive, in the neoadjuvant #neoadjuvant setting. #OvarianCancerAwareness #gyncsm #BRCA Treating before surgery buys the cleanest possible readout: the resected tumor itself. The co-primary endpoints are the safety of the full combination and pathologic complete response at debulking. A pathologic complete response, meaning no viable tumor left in the surgical specimen, is one of the most demanding endpoints in solid-tumor #oncology and a recognized marker of long-term benefit. The design also reads the mechanism directly. It looks for the chemokine switch, the rise in intratumoral CD8 cells with a favorable ratio to regulatory cells and a TCF1-positive phenotype, the falling inflammatory tone, and the specific signature of restored pulsed IL-12p70 against preserved bulk IL-12. The study is built to show whether the mechanism engaged, not only whether tumors shrank. Enrollment is expected to begin in the second half of 2026, and because the central readout is the surgical specimen rather than years of follow-up, the first mechanistic signals should arrive relatively early. 🏭 Why this is a platform, not a one-off The instructor cell at the center of this regimen is the same dendritic-cell platform Northwest Biotherapeutics has built its company around. #DCVax extended survival in Phase 3 glioblastoma (JAMA Oncology, 2023), and a UK marketing application is pending with MHRAgovuk. The same approach has already worked in ovarian cancer. At the University of Pennsylvania, a personalized whole-tumor dendritic-cell vaccine in recurrent ovarian cancer was well tolerated and induced broad antitumor T-cell responses that tracked with significantly longer survival, with two-year survival of one hundred percent in the immune responders against twenty-five percent in non-responders (Tanyi et al., Science Translational Medicine, 2018). Those dendritic cells were loaded with the patient's own whole tumor and activated toward the same type 1 program this regimen rebuilds. That is the proof of principle, and this trial is the more complete version of it. The dendritic cell here is engineered for higher, sustained IL-12p70. It is given in the front line, where the antigen supply is richest, rather than in heavily pretreated relapse. The suppressive microenvironment is reprogrammed in parallel rather than left intact, and the checkpoint is released at the end. The Penn vaccine carried the immune response largely on its own. This regimen clears the field for it first, then takes the brake off. The historical knock on personalized cell therapy was manufacturing: bespoke, hand-built, hard to scale. Northwest Biotherapeutics has been answering that directly. #Flaskworks #EDEN, the closed, automated manufacturing system the company acquired, standardizes production and removes the single-site hand manufacturing that limited earlier programs. The Sawston facility #Sawston in the UK, operated by #AdventBioServices, a wholly owned Northwest Biotherapeutics subsidiary, under MHRA good-manufacturing standards, is bringing its first Grade C suite online in 2026, a step anticipated to more than double capacity, with a dedicated leukapheresis clinic already running. The company has also added senior leadership to drive the platform, naming the biopharmaceutical veteran Dr. Annalisa Jenkins as a strategic adviser. The consequence is concrete. If the mechanism reads out in the resected tumor, the system that delivers it is already being built to scale, across the many solid tumors that run the same silencing cascade. One trial, read correctly, does not validate a single drug. It tests a repeatable way of rebuilding antitumor immunity. That reach is the point. The same instructor sits at the center of the silencing cascade across most solid tumors, which is why the dendritic-cell platform is framed around the approach itself rather than a single indication. A front-line ovarian readout that confirms the mechanism would be evidence for the method, not for one tumor type alone. The needle moves on the tissue, not on the thesis, and no paragraph substitutes for the pathology report. What the design offers is a complete, testable mechanism for durable immunity in ovarian cancer, paired with a manufacturing system already capable of producing it at scale. The readout in the resected tumor will speak for itself. Not financial advice. Do your own research. #DCVaxForBraelyn

Andrew Caravello, DO

10,459 görüntüleme • 3 ay önce

A 2025 Nature study revealed a surprisingly simple way aspirin might help fight cancer metastasis. Researchers discovered that cancer cells trick blood vessels into releasing a substance called thromboxane A2 (TXA2). This chemical then sends a signal that basically tells our immune system’s T-cells to “stand down,” making it easier for cancer to spread. Science nugget: In mouse models of breast, skin, and bowel cancer, aspirin blocked TXA2 production. This freed up the T-cells to attack more effectively, resulting in significantly fewer metastases. When scientists genetically removed the key protein (ARHGEF1) that receives the signal, metastasis dropped sharply — and aspirin had no extra effect, proving this is the main pathway. The study helps explain why some earlier human observational data showed potential protective effects (especially for colorectal cancer). However, these promising results are still from mice, and experts stress that we need proper clinical trials in humans to confirm who might benefit and what the risks are. Any use of aspirin for cancer-related reasons should only happen after talking to your doctor, due to side effects like increased bleeding risk. It’s a fascinating reminder that an old, cheap drug might still have hidden powers we’re only beginning to understand. Does this aspirin-cancer connection surprise you, or does it make you curious about what other everyday medicines might have undiscovered effects?
3:36

A 2025 Nature study revealed a surprisingly simple way aspirin might help fight cancer metastasis. Researchers discovered that cancer cells trick blood vessels into releasing a substance called thromboxane A2 (TXA2). This chemical then sends a signal that basically tells our immune system’s T-cells to “stand down,” making it easier for cancer to spread. Science nugget: In mouse models of breast, skin, and bowel cancer, aspirin blocked TXA2 production. This freed up the T-cells to attack more effectively, resulting in significantly fewer metastases. When scientists genetically removed the key protein (ARHGEF1) that receives the signal, metastasis dropped sharply — and aspirin had no extra effect, proving this is the main pathway. The study helps explain why some earlier human observational data showed potential protective effects (especially for colorectal cancer). However, these promising results are still from mice, and experts stress that we need proper clinical trials in humans to confirm who might benefit and what the risks are. Any use of aspirin for cancer-related reasons should only happen after talking to your doctor, due to side effects like increased bleeding risk. It’s a fascinating reminder that an old, cheap drug might still have hidden powers we’re only beginning to understand. Does this aspirin-cancer connection surprise you, or does it make you curious about what other everyday medicines might have undiscovered effects?

Camus

268,189 görüntüleme • 5 ay önce

Temperature and light are two of the most important considerations for optimal sleep. When we sleep our bodies naturally drop down in temperature, by .5-1 degrees, a warm room or bed negatively impacts sleep, the same goes for light in your room while sleeping. That's why I have blackout shades and sleep on an Eight Sleep Not only does EightSleep keep the bed cool, I've seen substantial improvements in my deep sleep, and, the part that I am most excited for is for women: they are invested in female science. they've rolled out a pregnancy & postpartum modes and a rapid cooling response to combat hot flashes which is incredible. We know that during these phases, temperature plays a big role in the poor sleep that women are experiencing. Outside of those life stages, women in general have higher temps during their luteal phase and perimenopause, both of which can reduce sleep quality. here is where a cool bed can make a big difference. with my code KAYLA, you can save up to $350 on Eightsleep at
1:22

Temperature and light are two of the most important considerations for optimal sleep. When we sleep our bodies naturally drop down in temperature, by .5-1 degrees, a warm room or bed negatively impacts sleep, the same goes for light in your room while sleeping. That's why I have blackout shades and sleep on an Eight Sleep Not only does EightSleep keep the bed cool, I've seen substantial improvements in my deep sleep, and, the part that I am most excited for is for women: they are invested in female science. they've rolled out a pregnancy & postpartum modes and a rapid cooling response to combat hot flashes which is incredible. We know that during these phases, temperature plays a big role in the poor sleep that women are experiencing. Outside of those life stages, women in general have higher temps during their luteal phase and perimenopause, both of which can reduce sleep quality. here is where a cool bed can make a big difference. with my code KAYLA, you can save up to $350 on Eightsleep at

Kayla Barnes-Lentz

14,945 görüntüleme • 27 gün önce

your agent reviewing its own work is not a check. it is a second opinion from the same source. this is the most common gap in agent systems and it hides in plain sight, because the step exists. there is a review. it just cannot do the thing you think it does. here is the mechanism. the model produced an output from a context. you then ask the same model, holding the same context, whether that output is correct. it answers fluently, because that is what it does. and the answer is drawn from the same distribution that produced the thing being judged. same weights, same window, same blind spots. if the reason the output is wrong is something the model does not know, the review does not know it either. if the reason is something the context does not contain, the review has the same context. the failure mode and the detector share a cause. > why it feels like it works because most of the time the output is fine, and the review says fine. agreement is not evidence of detection. a reviewer that says pass on everything agrees with reality most of the time too. what you actually want to measure is what happens on the cases that are wrong. that is the only place a check earns its name, and it is exactly the place where a self-review is weakest. there is research on this. Huang and colleagues at DeepMind showed at ICLR 2024 that intrinsic self-correction, revising without external grounding, does not reliably help and often makes things worse. > what to actually do move the check outside the model. a test that runs, a schema that validates, a file that exists or does not, an exit code from something you did not write. these are not smarter than the model. they are just not correlated with it, and that is the entire value. when the judgement genuinely needs a model, at minimum use a different family. same family means shared blind spots, and frontier judges measurably inflate scores for outputs that look like their own. and split the work by kind. anything objectively checkable goes to code. only the genuinely semantic calls go to a judge, and those get a rubric written as one line. a review inside the loop tells you the model is confident. a check outside it tells you whether the work is done. save this - then read the eval setup below
0:50

your agent reviewing its own work is not a check. it is a second opinion from the same source. this is the most common gap in agent systems and it hides in plain sight, because the step exists. there is a review. it just cannot do the thing you think it does. here is the mechanism. the model produced an output from a context. you then ask the same model, holding the same context, whether that output is correct. it answers fluently, because that is what it does. and the answer is drawn from the same distribution that produced the thing being judged. same weights, same window, same blind spots. if the reason the output is wrong is something the model does not know, the review does not know it either. if the reason is something the context does not contain, the review has the same context. the failure mode and the detector share a cause. > why it feels like it works because most of the time the output is fine, and the review says fine. agreement is not evidence of detection. a reviewer that says pass on everything agrees with reality most of the time too. what you actually want to measure is what happens on the cases that are wrong. that is the only place a check earns its name, and it is exactly the place where a self-review is weakest. there is research on this. Huang and colleagues at DeepMind showed at ICLR 2024 that intrinsic self-correction, revising without external grounding, does not reliably help and often makes things worse. > what to actually do move the check outside the model. a test that runs, a schema that validates, a file that exists or does not, an exit code from something you did not write. these are not smarter than the model. they are just not correlated with it, and that is the entire value. when the judgement genuinely needs a model, at minimum use a different family. same family means shared blind spots, and frontier judges measurably inflate scores for outputs that look like their own. and split the work by kind. anything objectively checkable goes to code. only the genuinely semantic calls go to a judge, and those get a rubric written as one line. a review inside the loop tells you the model is confident. a check outside it tells you whether the work is done. save this - then read the eval setup below

Hanako

14,325 görüntüleme • 1 ay önce

DEEP DIVE: HAVANA SYNDROME - CRIMSON MIST - THE VOICE OF GOD - AND THE EVIDENCE SHOWING EM RADIATION CAN MANIPULATE AND/OR DESTROY YOUR MIND (TWEET 1/12) Although the idea of physically affecting people with electromagnetic field (EMF) waves produced by 5G towers has been firmly relegated to the realm of conspiracy theory by most people, it seems there is an abundance of evidence showing that electromagnetic (EM) radiation in the microwave and millimeter-wave bands(1) can be deployed—and has been deployed—as a weapon that attacks the mind and body, causing serious, potentially permanent damage. And, at least indirectly, death. Here, we look at several key case scenarios wherein EM radiation in the microwave, millimeter-wave, and extremely low frequency (ELF) bands has been deployed as a weapon, including instances both acknowledged and unacknowledged by the mainstream press. Firstly, to establish a tangible sense of what directed millimeter radiation can do, here is a clip of the U.S. military's "Active Denial System" (ADS) in action. The ADS, also referred to as "the heat ray"(2), works by heating up people's skin with directed millimeter radiation(3). The Department of Defense (DOD) says "adverse reactions are extremely rare," but that the ADS can cause "skin blisters"(3). In the video shown here, we watch the ADS in action as marines and "other DOD representatives" observe the weapon being demonstrated on officials pretending to be in a "riotous crowd." The maximum distance for the weapon in the demonstration is seven football fields, or 2,520 feet. Note that when you see the men abruptly turn and run, that's because their skin is being superficially burned and they are experiencing a sensation similar to standing in front of an open oven door. In regard to real-world use, the ADS was deployed in 2010 with the United States military in the Afghanistan War, but was withdrawn without seeing combat(2). NPR also reported in September 2020 that a spokesperson for the Joint Forces Headquarters Command in Washington, D.C. confirmed that it had asked the National Guard if it had access to an ADS so "that [it] might be deployed against demonstrators in the nation's capital"(4). Although it, ultimately, was not. 1. There is an EMF legend tagged onto the end of this thread for clarity (tweet 12). Note 5G Wavelength is typically around 70 to 90 millimeters in length. Source: 2. Source: 3. Source: 4. Source:
1:48

DEEP DIVE: HAVANA SYNDROME - CRIMSON MIST - THE VOICE OF GOD - AND THE EVIDENCE SHOWING EM RADIATION CAN MANIPULATE AND/OR DESTROY YOUR MIND (TWEET 1/12) Although the idea of physically affecting people with electromagnetic field (EMF) waves produced by 5G towers has been firmly relegated to the realm of conspiracy theory by most people, it seems there is an abundance of evidence showing that electromagnetic (EM) radiation in the microwave and millimeter-wave bands(1) can be deployed—and has been deployed—as a weapon that attacks the mind and body, causing serious, potentially permanent damage. And, at least indirectly, death. Here, we look at several key case scenarios wherein EM radiation in the microwave, millimeter-wave, and extremely low frequency (ELF) bands has been deployed as a weapon, including instances both acknowledged and unacknowledged by the mainstream press. Firstly, to establish a tangible sense of what directed millimeter radiation can do, here is a clip of the U.S. military's "Active Denial System" (ADS) in action. The ADS, also referred to as "the heat ray"(2), works by heating up people's skin with directed millimeter radiation(3). The Department of Defense (DOD) says "adverse reactions are extremely rare," but that the ADS can cause "skin blisters"(3). In the video shown here, we watch the ADS in action as marines and "other DOD representatives" observe the weapon being demonstrated on officials pretending to be in a "riotous crowd." The maximum distance for the weapon in the demonstration is seven football fields, or 2,520 feet. Note that when you see the men abruptly turn and run, that's because their skin is being superficially burned and they are experiencing a sensation similar to standing in front of an open oven door. In regard to real-world use, the ADS was deployed in 2010 with the United States military in the Afghanistan War, but was withdrawn without seeing combat(2). NPR also reported in September 2020 that a spokesperson for the Joint Forces Headquarters Command in Washington, D.C. confirmed that it had asked the National Guard if it had access to an ADS so "that [it] might be deployed against demonstrators in the nation's capital"(4). Although it, ultimately, was not. 1. There is an EMF legend tagged onto the end of this thread for clarity (tweet 12). Note 5G Wavelength is typically around 70 to 90 millimeters in length. Source: 2. Source: 3. Source: 4. Source:

Sense Receptor

109,212 görüntüleme • 3 yıl önce